Vischer announced the addition of Karin Graf (pictured) to the firm’s litigation and arbitration team, in the role of partner. Graf assumes her new role as of September 1st. Graf brings with her more
Tags :Vischer
Vischer’s dispute resolution team successfully represented a Swiss bank in a multi-faceted conflict, defending against allegations of corruption and breaches of contract as well as massive claims for damages. The dispute included commercial court
Biopharmaceutical company Relief Theraputics Holding, has a binding agreement with two institutional U.S. investors completed. The contract provides for the purchase of Relief shares with a total value of CHF 15 million, which come from
Atlas Antibodies, a global developer of advanced reagents for biomedical research based in Sweden, has agreed to acquire Evitria Group from its shareholders. The transaction closed on August 5, 2021. Vischer advised the sellers on this
Rigeto portfolio company Swissphone acquires instaSolution, a provider of modern and efficient communication and management solutions in the areas of alerting, crisis management, mobile collaboration, messaging and IoT. The transaction closed on July 16, 2021. Vischer
Relief Therapeutics Holding, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, has issued 1,000,000,000 additional registered shares out of the authorised share capital approved by the Annual
H.C. Wainwright acted as sole placement agent in connection to the private placement of 71,428,572 shares in Relief Therapeutics Holding, a Swiss biopharmaceutical company listed at SIX Swiss Exchange, at a price of CHF 0.21 per
International hotel group Meininger manages its successful market entry in Switzerland and opens new hotels in Zürich Greencity (174 rooms, 582 beds) and Genève Centre Charmilles (104 rooms, 362 beds). Vischer advises Meininger on any Swiss
Kuros Biosciences, a bone graft technologies company, has entered into a royalty purchase agreement with Xoma Corporation, under which Xoma has purchased a proportion of the potential future pre-commercial milestone payments and all the potential
Vischer has acted as legal counsel to TargImmune Therapeutics, a private Swiss-based biotechnology firm, on the closing of its 2021 financing round, raising CHF 17.7 million. The Vischer legal team was led by Matthias Staehelin (pictured) with
